The transforming growth factor-beta signaling pathway involvement in cardiovascular lesions in mucopolysaccharidosis-I

JIMD Reports

Volumn 7, Issue , 2013, Pages 55-58

  Yano, S ^a   Li, C ^a   Pavlova, Z ^b  

^a LAC USC MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Coronary artery lesion; Dermatan sulfate; Enzyme replacement therapy; Hypertrophic cardiomyopathy; Valvular lesion

Indexed keywords

EID: 84932092835     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2012_141     Document Type: Chapter

References (15)

1. Brosius FC, Roberts WC (1981) Coronary artery disease in the Hurler syndrome: qualitative and quantitative analysis of the extent of coronary narrowing at necropsy in six children. Am J Cardiol 47 (3):649–653
2. Hinek A, Wilson SE (2000) Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 156 (3):925–938
3. Hobbs JR, High-Jones K, Barrett AJ et al (1981) Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 2 (8249):709–712
4. Karnik SK, Brooke BS, Bayes-Genis A et al (2003) A critical role of elastin signaling in vascular morphogenesis and disease. Development 130(2):411–423
5. Khan R, Sheppard R (2006) Fibrosis in heart disease: understanding the role of transforming growth factor-β1 in cardiomyopathy, valvular disease and arrhythmia. Immunology 118:10–24
6. Krovetz LJ, Lorincz AE, Schiebler GL (1965) Cardiovascular manifestations of the Hurler syndrome: hemodynamic and angiocardio-graphic observations in 15 patients. Circulation 31:132–141
7. Lyons JA, Dickson P, Wall J et al (2011) Arterial pathology in canine mucopolysaccharidosis-1 and response to therapy. Lab Invest 91 (5):665–674
8. Ma X, Tittiger M, Knutsen RH et al (2008) Upregulation of elastase proteins results in aortic dilation in mucopolysaccharidosis I mice. Mol Genet Metab 94(3):298–304
9. Matalon R, Dorfman A (1968) The structure of acid mucopolysac-charides produced by hurler fibroblasts in tissue culture. Proc Natl Acad Sci USA 60(1):179–185
10. Pokharel S, Rasoul S, Roks AJM et al (2002) N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension 40:155–161
11. Renteria VG, Ferrans VJ, Roberts WC (1976) The heart in the Hurler syndrome: gross, histologic and ultrastructural observations in five necropsy cases. Am J Cardiol 38(4):487–501
12. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J (2007) TGF-β signaling in vascular fibrosis. Cardiovasc Res 74:196–206
13. Sifuentes M, Doroshow R, Hoft R et al (2007) A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90(2):171–180
14. Venkatesan N, Ouzzine M, Kolb M, Netter P, Ludwig MS (2011) Increased deposition of chondroitin/dermatan sulfate glycosaminoglycan and upregulation of β1,3-glucuronosyltransferase I in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 300(2):L191–L203
15. Yano S, Moseley K, Pavlova Z (2009) Postmortem studies on a patient with mucopolysaccharidosis type I: histopathological findings after one year of enzyme replacement therapy. J Inherit Metab Dis. doi 10.1007/s10545-009-1057-4